ReviewFrontiers in immunology2025
Depression and anxiety in inflammatory bowel disease: mechanisms and emerging therapeutics targeting the microbiota-gut-brain axis.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research hotspots, context, and future directions of ulcerative colitis comorbid with depression from 2006 to 2025: a bibliometric and visualization analysis.Frontiers in medicine · 2026Pooled it
- Optimising clinical trial design choices in inflammatory bowel disease.BMJ open gastroenterology · 2026Review
- Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Prenylated p-Coumaric Acid Derivatives Mitigate Neurobehavioral and Neuroinflammatory Alterations Associated with Experimental Colitis.International journal of molecular sciences · 2026Article
- Predictors of Stress, Anxiety, Depression and Quality of Life in Patients Diagnosed with Chronic Inflammatory Bowel Disease in Romania: A Cross-Section Observational Case-Report Study.Journal of clinical medicine · 2026Article
- Targeting the gut-immune-brain axis: pharmacological insights from depression in inflammatory bowel disease.Frontiers in pharmacology · 2026Review
- Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases.Frontiers in immunology · 2026Review
- Comorbidity Between Mood Disorders and Chronic Somatic Diseases, With a Focus on Cardiometabolic Disease, and Its Mechanistic Crosstalk.Depression and anxiety · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), represents a group of chronic, relapsing intestinal inflammatory disorders with incompletely understood etiology. Depression and anxiety, as prevalent psychiatric conditions, exhibit rising incidence rates; notably, IBD patients demonstrate heightened susceptibility to these disorders compared to the general population, thereby exacerbating disease burden and increasing risks of adverse clinical outcomes. Emerging evidence reveals shared pathophysiological mechanisms between IBD and depression/anxiety. This review specifically addresses depression and anxiety within the IBD disease context, integrating recent epidemiological evidence and risk factors. Centered on the gut-brain axis framework, we examine mechanistic underpinnings through two interconnected pathways: gut dysbiosis and neuroimmune interactions mediated by inflammatory cytokines and neurotransmitters. Finally, we explore therapeutic interventions for depression and anxiety in IBD based on these mechanistic insights, aiming to advance clinical and public health management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.